The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
Open accessAbstract
The poor prognosis of patients with aggressive and invasive cancers combined with toxic effects and short half-life of currently available treatments necessitate development of more effective tumor selective therapies. Mesenchymal stem cells (MSCs) are emerging as novel cell-based delivery agents; however, a thorough investigation addressing their therapeutic potential and fate in different cancer models is lacking. In this study, we explored the engineering potential, fate, and therapeutic efficacy of human MSCs in a highly malignant and invasive model of glioblastoma. We show that engineered MSC retain their “stem-like” properties, survive longer in mice with gliomas than in the normal brain, and migrate extensively toward gliomas. We also show that MSCs are resistant to the cytokine tumor necrosis factor apoptosis ligand (TRAIL) and, when engineered to express secreted recombinant TRAIL, induce caspase-mediated apoptosis in established glioma cell lines as well as CD133-positive primary glioma cells in vitro. Using highly malignant and invasive human glioma models and employing real-time imaging with correlative neuropathology, we demonstrate that MSC-delivered recombinant TRAIL has profound anti-tumor effects in vivo. This study demonstrates the efficacy of diagnostic and therapeutic MSC in preclinical glioma models and forms the basis for developing stem cell-based therapies for different cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pluripotency of mesenchymal stem cells derived from adult marrow
Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., et al. (2002) · Nature · doi:10.1038/nature00870 · Cited by 5,518
RetractedIdentification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,197
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Imitola, J., Raddassi, K., Park, K. I., Mueller, F.-J., Nieto, M., Teng, Y. D., Frenkel, D., Li, J., Sidman, R. L., Walsh, C. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408258102 · Cited by 1,057
Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., Chen, J., Hentschel, S., Vecil, G., Dembinski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1874 · Cited by 1,035
Son, B., Marquez‐Curtis, L. A., Kucia, M., Wysoczynski, M., Turner, A. R., Ratajczak, J., Ratajczak, M. Z., & Janowska‐Wieczorek, A. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0271 · Cited by 641
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
Almasan, A., & Ashkenazi, A. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00029-7 · Cited by 553
Adipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431
Teng, Y. D., Frenkel, D., Nieto, M., Müeller, F.-J., Park, K. I., Raddassi, K., Imitola, J., Li, J., Sidman, R. L., Walsh, C. A., et al. (2004) · Cited by 421
Corsten, M. F., Miranda, R., Kasmieh, R., Krichevsky, A. M., Weissleder, R., & Shah, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1045 · Cited by 406
Self-citationWakimoto, H., Kesari, S., Farrell, C. J., Curry, W. T., Zaupa, C., Aghi, M., Kuroda, T., Stemmer-Rachamimov, A., Shah, K., Liu, T.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3886 · Cited by 361
Self-citationExpansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow
Mareschi, K., Ferrero, I., Rustichelli, D., Aschero, S., Gammaitoni, L., Aglietta, M., Madon, E., & Fagioli, F. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20681 · Cited by 318
Mesenchymal Stem Cells Derived from Human Adipose Tissues Favor Tumor Cell Growth in vivo
Yu, J. M., Jun, E. S., Bae, Y. C., & Jung, J. S. (2008) · Stem Cells and Development · doi:10.1089/scd.2007.0181 · Cited by 271
Stem and progenitor cell-mediated tumor selective gene therapy
Aboody, K. S., Najbauer, J., & Danks, M. K. (2008) · Gene Therapy · doi:10.1038/gt.2008.41 · Cited by 270
Mesenchymal Stem Cells Effectively Deliver an Oncolytic Adenovirus to Intracranial Glioma
Sonabend, A. M., Ulasov, I. V., Tyler, M. A., Rivera, A. A., Mathis, J. M., & Lesniak, M. S. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0758 · Cited by 254
Palumbo, R., Galvez, B. G., Pusterla, T., De Marchis, F., Cossu, G., Marcu, K. B., & Bianchi, M. E. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704015 · Cited by 250
The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo
Lu, Y.-R., Yuan, Y., Wang, X.-J., Wei, L.-L., Chen, Y.-N., Cong, C., Li, S.-F., Long, D., Tan, W.-D., Mao, Y.-Q., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.2.5296 · Cited by 225
Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy
Hamada, H., Kobune, M., Nakamura, K., Kawano, Y., Kato, K., Honmou, O., Houkin, K., Matsunaga, T., & Niitsu, Y. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00032.x · Cited by 208
(2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)81130-3 · Cited by 208
Verhaegen, M., & Christopoulos, T. K. (2002) · Analytical Chemistry · doi:10.1021/ac025742k · Cited by 204
Lüttichau, I. V., Notohamiprodjo, M., Wechselberger, A., Peters, C., Henger, A., Seliger, C., Djafarzadeh, R., Huss, R., & Nelson, P. J. (2005) · Stem Cells and Development · doi:10.1089/scd.2005.14.329 · Cited by 202
Schmidt, N. O., Przylecki, W., Yang, W., Ziu, M., Teng, Y. D., Kim, S. U., Black, P. M., Aboody, K. S., & Carroll, R. S. (2005) · Neoplasia · doi:10.1593/neo.04781 · Cited by 199
MCP-1 induces migration of adult neural stem cells
Widera, D., Holtkamp, W., Entschladen, F., Niggemann, B., Zänker, K., Kaltschmidt, B., & Kaltschmidt, C. (2004) · European Journal of Cell Biology · doi:10.1078/0171-9335-00403 · Cited by 194
Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines
Birnbaum, T., Roider, J., Schankin, C. J., Padovan, C. S., Schichor, C., Goldbrunner, R., & Straube, A. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9332-4 · Cited by 188
Griffith, T. S., Anderson, R. D., Davidson, B. L., Williams, R. D., & Ratliff, T. L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2886 · Cited by 183
Glioma therapy and real‐time imaging of neural precursor cell migration and tumor regression
Shah, K., Bureau, E., Kim, D., Yang, K., Tang, Y., Weissleder, R., & Breakefield, X. O. (2005) · Annals of Neurology · doi:10.1002/ana.20306 · Cited by 182
Self-citationHuman Mesenchymal Stem Cells Maintain Transgene Expression during Expansion and Differentiation
Lee, K., Majumdar, M. K., Buyaner, D., Hendricks, J. K., Pittenger, M. F., & Mosca, J. D. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0327 · Cited by 164
Human Fetal Mesenchymal Stem Cells as Vehicles for Gene Delivery
Chan, J., O'Donoghue, K., de la Fuente, J., Roberts, I. A., Kumar, S., Morgan, J. E., & Fisk, N. M. (2005) · STEM CELLS · doi:10.1634/stemcells.2004-0138 · Cited by 163
mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells
Panner, A., James, C. D., Berger, M. S., & Pieper, R. O. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.20.8809-8823.2005 · Cited by 156
Miletić, H., Fischer, Y., Litwak, S. A., Giroglou, T., Waerzeggers, Y., Winkeler, A., Li, H., Himmelreich, U., Lange, C., Stenzel, W., et al. (2007) · Molecular Therapy · doi:10.1038/mt.sj.6300155 · Cited by 155
Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo
Shah, K., Tang, Y., Breakefield, X. O., & Weissleder, R. (2003) · Oncogene · doi:10.1038/sj.onc.1206748 · Cited by 131
Self-citationMarrow Stromal Cells for Interleukin-2 Delivery in Cancer Immunotherapy
Stagg, J., Lejeune, L., Paquin, A., & Galipeau, J. (2004) · Human Gene Therapy · doi:10.1089/104303404323142042 · Cited by 111
Approaches to Utilize Mesenchymal Progenitor Cells as Cellular Vehicles
Pereboeva, L., Komarova, S., Mikheeva, G., Krasnykh, V. N., & Curiel, D. T. (2003) · Stem Cells · doi:10.1634/stemcells.21-4-389 · Cited by 110
Efficient Lentiviral Transduction and Improved Engraftment of Human Bone Marrow Mesenchymal Cells
Damme, A. V., Thorrez, L., Ma, L., Vandenburgh, H. H., Eyckmans, J., Dell’Accio, F., Bari, C. D., Luyten, F. P., Lillicrap, D., Collen, D., et al. (2005) · Stem Cells · doi:10.1634/stemcells.2003-0106 · Cited by 101
Shah, K., Hingtgen, S., Kasmieh, R., de Figueiredo, J. L., García-García, E., Martínez-Serrano, A., Breakefield, X. O., & Weissleder, R. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0296-08.2008 · Cited by 98
Self-citationReversal of Tumor-Mediated Immunosuppression
Vieweg, J., Su, Z. Z., Dahm, P., & Kusmartsev, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1924 · Cited by 93
Neural stem cell migration toward gliomas in vitro
Heese, O., Disko, A., Zirkel, D., Westphal, M., & Lamszus, K. (2005) · Neuro-Oncology · doi:10.1215/s1152851704000754 · Cited by 92
Inducible Release of TRAIL Fusion Proteins from a Proapoptotic Form for Tumor Therapy
Shah, K., Tung, C., Yang, K. S., Weissleder, R., & Breakefield, X. O. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3516 · Cited by 87
Self-citationTumor Therapy Mediated by Lentiviral Expression of shBcl-2 and S-TRAIL
Kock, N., Kasmieh, R., Weissleder, R., & Shah, K. (2007) · Neoplasia · doi:10.1593/neo.07223 · Cited by 83
Self-citationMaeurer, M. J., Martin, D. M., Castelli, C., Elder, E. M., Leder, G. H., Storkus, W. J., & Lotze, M. T. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01527407 · Cited by 76
New approaches to primary brain tumor treatment
Sathornsumetee, S., & Rich, J. N. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000231473.00030.1f · Cited by 55
Dirks, P. B. (2005) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2004.11.004 · Cited by 17
Research works printed but not linked: 4
- 10.1038/sj.mt.6300155 · doi:10.1038/sj.mt.6300155
- 10.1006/excr.1999.4760 · doi:10.1006/excr.1999.4760
- M Ehtesham, et al., Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 62, 7170–7174 (2002).
- 10.3171/jns.2006.105.1.88 · doi:10.3171/jns.2006.105.1.88
Cited by
Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
Mesenchymal Stem Cells as Therapeutics
Parekkadan, B., & Milwid, J. M. (2010) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070909-105309 · Cited by 759
Shattering barriers toward clinically meaningful MSC therapies
Levy, O., Kuai, R., Siren, E. M. J., Bhere, D., Milton, Y., Nissar, N., De Biasio, M., Heinelt, M., Reeve, B., Abdi, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba6884 · Cited by 694
Self-citationMesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy
Baglio, S. R., Pegtel, D. M., & Baldini, N. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00359 · Cited by 542
Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2
Lawler, P. R., & Lawler, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006627 · Cited by 532
Metadata
- Authors
- Sasportas, L. S., Kasmieh, R., Wakimoto, H., Hingtgen, S., van de Water, J. A. J. M., Mohapatra, G., Figueiredo, J. L., Martuza, R. L., Weissleder, R., & Shah, K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-03-24
- Volume
- 106
- Issue
- 12
- Pages
- 4822-4827
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2000534793
- Cited by
- 455
- References
- 45
- FWCI
- 17.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.